PMID- 30474301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230201
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 120
IP  - 5
DP  - 2019 May
TI  - Retracted: MicroRNA-34a inhibit hepatocellular carcinoma progression by 
      repressing hexokinase-1.
PG  - 7147-7153
LID - 10.1002/jcb.27988 [doi]
AB  - Hepatocellular carcinoma (HCC) is known as a frequent type of primary cancer in 
      the liver, and it is the third-most common cause of cancer-related death all over 
      the world. However, the molecular mechanism in the progression of HCC is still 
      unclear. The current study was designed to investigate the expression and 
      function of microRNA-34a (miR-34a) in HCC. In HCC tissues and cells, the 
      expression levels of miR-34a were analyzed by quantitative real-time polymerase 
      chain reaction. The association between the level of miR-34a and hexokinase 
      (HK)-1 was also investigated via luciferase reporter assay. Cell viability and 
      proliferation were detected by 
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and flow 
      cytometry. To assess whether miR-34a can limit tumor growth in vivo, animal 
      models and terminal deoxynucleotidyl transferase dUTP nick end labeling assay 
      were used for examining the role of miR-34a on the development of HCC and cell 
      apoptosis. The expression level of miR-34a was reduced in HCC samples and cells. 
      The expression of miR-34a was associated with the viability and proliferation 
      capacity of HCC cells, and miR-34a could inhibit HCC cells proliferation by 
      inhibiting HK1. In the mouse model of HCC, volumes and weight of the tumors were 
      significantly decreased by transfection with miR-34a mimic compared with the 
      control group. Furthermore, miR-34a mimics could induce apoptosis in a greater 
      proportion of cells compared with the control group. Taken together, the data may 
      provide some novel insights into the molecular mechanism of miR-34a and HK1 in 
      the progression of HCC. Thus, miR-34a/HK1 axis might be a novel promising 
      therapeutic target for treating HCC.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Zhou, Yitong
AU  - Zhou Y
AD  - Department of Surgery, Changchun Medical College, Changchun, Jilin, China.
FAU - Liu, Kai
AU  - Liu K
AD  - Department of Hepatobiliary Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
FAU - Liu, Yahui
AU  - Liu Y
AD  - Department of Hepatobiliary Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
FAU - Tan, Ludong
AU  - Tan L
AUID- ORCID: 0000-0002-1818-953X
AD  - Department of Hepatobiliary Surgery, The First Hospital of Jilin University, 
      Changchun, Jilin, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20181126
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
SB  - IM
RIN - J Cell Biochem. 2022 Feb;123(2):494. PMID: 35188990
OTO - NOTNLM
OT  - cell proliferation
OT  - hepatocellular carcinoma (HCC)
OT  - hexokinase (HK)-1
OT  - microRNA-34a (miR-34a)
EDAT- 2018/11/27 06:00
MHDA- 2018/11/27 06:01
CRDT- 2018/11/27 06:00
PHST- 2018/08/18 00:00 [received]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2018/11/27 06:01 [medline]
PHST- 2018/11/27 06:00 [entrez]
AID - 10.1002/jcb.27988 [doi]
PST - ppublish
SO  - J Cell Biochem. 2019 May;120(5):7147-7153. doi: 10.1002/jcb.27988. Epub 2018 Nov 
      26.